Nearly two years after Takeda pulled its US marketing application for a vaccine against dengue fever, MSD has advanced a rival shot into phase 3. The international MOBILIZE-1 trial is looking at a ...
A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by the FDA, and the partners have now withdrawn a filing intended to get the ...
The CyberWire is an independent voice delivering concise, accessible, and relevant cybersecurity news briefings and cybersecurity podcasts to people all across the globe.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback